FUS-medicated Circ_0002099 could promote the epithelial-mesenchymal transition process in BLCA progression via miR-217-5p/miR-103a-3p/KRAS axis-WNT/beta-catenin axi.
Circ_0002099 is a novel molecular therapeutic target for bladder cancer.